Ascendis Pharma A/S (ASND) Stock: Price, Forecast & Analyst Target
Ascendis Pharma A/S (ASND) — MoonshotScore 90/100 (Exceptional band), calculated Oct 27, 2026. Price $245.15 (+0.73%), as of the Oct 26, 2026 trading session; market cap $16.1B. Expected results Nov 11, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Ascendis Pharma A/S · ASND · NASDAQ · Healthcare · Biotechnology
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments.
Price as of Oct 26, 2026
Key Statistics
MoonshotScore v2 · Ascendis Pharma A/S (ASND)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a strong balance sheet and elite growth, with no real weak spot — fairly priced, so not a bargain entry; the market is already moving on it. The score also carries a risk penalty for reported profit not backed by cash flow. Business Quality: Elite; Financial Safety: Sound; Valuation: Rich; Growth Durability: Compounding; Momentum: Rising.
- quarterly revenue $385M (Q2 FY2026, quarter ended Jun 30, 2026)
- EPS beat 5 of 8
- Altman Z 9.46 · Piotroski F 6
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 88 | Exceptional | |
| 89 | Exceptional | |
| 89 | Exceptional | |
| 89 | Exceptional | |
| 90 | Exceptional | |
| 90 | Exceptional |
The score was 90 in the stored Oct 26, 2026 snapshot and remains 90 in the current publication computed Oct 27, 2026 (0); the largest pillar moves were Momentum +2 and Valuation -1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $245.15 |
| Change on the day | +0.73% |
| 52-week range | $188.07–$282.15 |
| Market capitalisation | $16.1B |
| Price / earnings (trailing) | 18.18 |
| Shares traded on the day | 545.0K |
| Beta (volatility vs the S&P 500) | 0.37 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
Even with these investments, we expect to generate more than EUR 500 million in cash flow from operating activities this year.
Scott Smith · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for Ascendis Pharma A/S (ASND): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 12, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 11, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.
Readings on this page are from Oct 27, 2026, except a card that shows its own read date.
Watch the ASND film — every key number, told as a short cinematic story
~2 min · open the film
What is Ascendis Pharma A/S (ASND), and what does it report?
Short answer · as of
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Ascendis Pharma A/S (ASND) is listed on NASDAQ. Ascendis Pharma A/S (ASND) is classified as Healthcare / Biotechnology. SEC filing business address: Tuborg Boulevard 12, Hellerup. It employs 1,189 people and is led by Jan Moller Mikkelsen. In Q2 FY2026 it reported revenue of $385M and net income of $235M. The market values it at $16.1B.
What do the latest results show for Ascendis Pharma A/S (ASND)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $385M. Against analyst estimates the company has EPS beat 5 of 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $387.48M Aug 13, 2026
- Latest report · revenue estimate
- $376.75M Aug 13, 2026
- Latest report · revenue vs estimate
- Above estimate Aug 13, 2026
- Latest report · EPS vs estimate
- Above estimate Aug 13, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 13, 2026 | $387.48M | $376.75M | $3.2900 | $1.7100 |
| May 7, 2026 | $284.92M | $308.93M | $0.3200 | $0.1876 |
| Feb 11, 2026 | $344.84M | $292.26M | −$0.6400 | −$0.0600 |
| Nov 12, 2025 | $250.22M | $302.60M | −$1.1700 | −$0.4100 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $385M | $235M | $3.44 (diluted) |
| Q1 FY2026 | $280M | $714M | $11.07 (diluted) |
| Q4 FY2025 | $274M | -$37M | -$0.60 (diluted) |
| Q3 FY2025 | $239M | -$68M | -$1.12 (diluted) |
What are the financial strengths and risks for Ascendis Pharma A/S (ASND)?
Short answer
The MoonshotScore pillars rate business quality, balance-sheet strength, durable growth, positive momentum as strengths. The distress and quality screens read Altman Z 9.46 · Piotroski F 6. Trailing ratios: ROE 190.4% · ROA 33.1% · current ratio 2.99 · earnings yield 5.9% · free-cash-flow yield 2.7%.
What should you watch next at Ascendis Pharma A/S (ASND)?
Short answer · as of
The next earnings report is expected on Nov 11, 2026. Current published price targets run low $268.00 · high $344.00 · consensus $307.85 · median $319.00 against a quoted price of $245.15 (as of Oct 26, 2026).
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
Even with these investments, we expect to generate more than EUR 500 million in cash flow from operating activities this year.
Scott Smith ·
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
Checked against the records this page reads, on the dates shown above.
How does Ascendis Pharma A/S compare with its peers?
Short answer
Ascendis Pharma A/S's score ranks tied for 8th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $65.11 Oct 26, 2026 | $16.4B | 98 5-pillar Oct 27, 2026 | |
| $126.80 Oct 26, 2026 | $14.4B | 98 5-pillar Oct 27, 2026 | |
| $113.31 Oct 26, 2026 | $23.0B | 98 5-pillar Oct 27, 2026 | |
| $587.46 Oct 26, 2026 | $25.2B | 98 5-pillar Oct 27, 2026 | |
| $312.93 Oct 26, 2026 | $9.26B | 98 5-pillar Oct 27, 2026 | |
| $72.55 Oct 23, 2026 | $11.4B | 93 5-pillar Oct 27, 2026 | |
| $32.23 Oct 26, 2026 | $9.11B | 91 5-pillar Oct 27, 2026 | |
| Ascendis Pharma A/S (ASND) — this page | $245.15 | $16.1B | 90 |
| $145.87 Oct 26, 2026 | $14.8B | 90 5-pillar Oct 27, 2026 | |
| $86.31 Oct 26, 2026 | $9.33B | 87 5-pillar Oct 27, 2026 | |
| $55.75 Oct 26, 2026 | $10.8B | 65 5-pillar Oct 27, 2026 | |
| $44.69 Oct 26, 2026 | $27.5B | 63 5-pillar Oct 27, 2026 | |
| $183.68 Oct 26, 2026 | $39.4B | 54 5-pillar Oct 27, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $268.00 – $344.00
- Consensus target
- $307.85
- Median target
- $319.00
Consensus record · Captured .
Measured against a quoted price of $245.15 (as of Oct 26, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 8, 2026
- Transactions
- 14
- Identified insiders
- 5
- Purchases
- 9
- Sales
- 3
- Other transactions
- 2
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 334 Period end Jun 30, 2026
- Previous quarter · holders
- 291 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Ra Capital Management, L.P. | 10,281,496 |
| T. Rowe Price Investment Management, INC. | 6,754,846 |
| Avoro Capital Advisors LLC | 5,111,111 |
| Westfield Capital Management Co LP | 4,798,267 |
| Jupiter Topco LLC | 3,648,772 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Ascendis Pharma A/S (ASND)?
ASND Healthcare Stock FAQ
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How does the TransCon pipeline extend beyond SKYTROFA?
The platform includes endocrine programs for hypoparathyroidism, achondroplasia and adult growth hormone deficiency, alongside oncology candidates. Their progress could broaden Ascendis beyond its current commercial concentration.
Are institutions increasing exposure during Ascendis Pharma’s commercial transition?
The reported institutional holder count increased, with specialist healthcare investors among the largest disclosed positions. That shows wider institutional participation, but it does not establish why any holder owns the shares.
What is the ASND stock price today?
The last price recorded on this page for Ascendis Pharma A/S (ASND) is $245.15, as of the Oct 26, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ASND price target?
The analyst consensus price target for Ascendis Pharma A/S (ASND) is $307.85 (range $268.00 to $344.00, median $319.00), per FMP data captured Oct 27, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (54 figures)
The 54 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Scott Smith (Aug 13, 2026): Even with these investments, we expect to generate more than EUR 500 million in cash flow from operating activities this year. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | Tuborg Boulevard 12, Hellerup | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "Tuborg Boulevard 12, Hellerup, CR, 2900, DK". |
FMP — 44 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $245.15 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-27T08:44:48.776Z. | |
px.change | Change on the day | +0.73% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $16.1B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-26. FMP quote timestamp: 2026-10-26T20:00:01.000Z. Captured from FMP at 2026-10-27T08:44:47.651Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
earn.next | Next earnings date | Nov 11, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
id.business_summary | Business description (FMP excerpt) | Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | +$1.78 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $385M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $188.07–$282.15 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 18.18 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 545.0K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.37 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Biotechnology | FMP | Financial Modeling Prep (FMP) company profile — The company's SEC filings classify it under SIC 2834 — Pharmaceutical Preparations. | |
id.employees | Employees | 1,189 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
id.ceo | Chief executive | Jan Moller Mikkelsen | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_income | Net income, Q2 FY2026 | $235M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history.depth.2026-08-13.revenue_actual | Revenue · reported — report date 2026-08-13 | $387.48M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-13.revenue_estimated | Revenue · estimate — report date 2026-08-13 | $376.75M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-13.eps_actual | EPS · reported — report date 2026-08-13 | $3.2900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-13.eps_estimated | EPS · estimate — report date 2026-08-13 | $1.7100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.revenue_actual | Revenue · reported — report date 2026-05-07 | $284.92M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.revenue_estimated | Revenue · estimate — report date 2026-05-07 | $308.93M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.eps_actual | EPS · reported — report date 2026-05-07 | $0.3200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.eps_estimated | EPS · estimate — report date 2026-05-07 | $0.1876 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-11.revenue_actual | Revenue · reported — report date 2026-02-11 | $344.84M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-11.revenue_estimated | Revenue · estimate — report date 2026-02-11 | $292.26M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-11.eps_actual | EPS · reported — report date 2026-02-11 | −$0.6400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-11.eps_estimated | EPS · estimate — report date 2026-02-11 | −$0.0600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-12.revenue_actual | Revenue · reported — report date 2025-11-12 | $250.22M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-12.revenue_estimated | Revenue · estimate — report date 2025-11-12 | $302.60M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-12.eps_actual | EPS · reported — report date 2025-11-12 | −$1.1700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-12.eps_estimated | EPS · estimate — report date 2025-11-12 | −$0.4100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
earn.pt | Stored analyst price targets | low $268.00 · high $344.00 · consensus $307.85 · median $319.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 27, 2026 · Coverage not supplied | |
earn.pt_range | Analyst price target, low to high | $268.00 – $344.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 27, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $307.85 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 27, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $319.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 27, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 14 transactions · 9 purchases, 3 sales, 2 other transactions · 5 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Sep 8, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.holders | Reporting holders | 334 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 291 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Ra Capital Management, L.P. — shares in provider snapshot | 10,281,496 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | T. Rowe Price Investment Management, INC. — shares in provider snapshot | 6,754,846 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Avoro Capital Advisors LLC — shares in provider snapshot | 5,111,111 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Westfield Capital Management Co LP — shares in provider snapshot | 4,798,267 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Jupiter Topco LLC — shares in provider snapshot | 3,648,772 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 3 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 5 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-26 | |
fin.scores | Distress and quality screens | Altman Z 9.46 · Piotroski F 6 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-26 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 190.4% · ROA 33.1% · current ratio 2.99 · earnings yield 5.9% · free-cash-flow yield 2.7% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 2 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history.depth.2026-08-13.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($387.48M) with the recorded estimate ($376.75M) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-13.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($3.2900) with the recorded estimate ($1.7100) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 3 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 90 of 100 · Exceptional · pillars 98 / 76 / 36 / 99 / 76 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 90 (stored snapshot Oct 26, 2026) → 90 (current publication computed Oct 27, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. | |
gap.statement_currency | Statement currency limitation | Detailed statement figures are not shown because their conversion to USD has not been verified. | OURS | Stock Expert AI currency-basis check |
Fact-family notes
- Earnings-history note. Source series as of 2026-08-13. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-13.revenue_actual,earn.history.depth.2026-08-13.revenue_estimated,earn.history.depth.2026-08-13.revenue_actual.comparison,earn.history.depth.2026-08-13.eps_actual.comparison,earn.history.depth.2026-08-13.eps_actual,earn.history.depth.2026-08-13.eps_estimated,earn.history.depth.2026-05-07.revenue_actual,earn.history.depth.2026-05-07.revenue_estimated,earn.history.depth.2026-05-07.eps_actual,earn.history.depth.2026-05-07.eps_estimated,earn.history.depth.2026-02-11.revenue_actual,earn.history.depth.2026-02-11.revenue_estimated,earn.history.depth.2026-02-11.eps_actual,earn.history.depth.2026-02-11.eps_estimated,earn.history.depth.2025-11-12.revenue_actual,earn.history.depth.2025-11-12.revenue_estimated,earn.history.depth.2025-11-12.eps_actual,earn.history.depth.2025-11-12.eps_estimated.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Institutional ownership (13F) | Holders: 333; Quarter: 2026-06-30; Holders previous quarter: 291 13F filings are quarterly and lag the quarter end by up to 45 days. | 2026-06-30 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings |
| Largest 5 institutional holders | Captured record · 5 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings |
Data provided for informational purposes only.